User account menu Search Menu Home Investors Novartis Financial Data Fixed-Income Securities Fixed-Income Securities Sustainability-linked bond USD securities CHF securities EUR securities USD fixed-income securities Issuer Amount (in millions) Coupon Maturity Novartis Capital Corp. 1,000 2.400% 2022 Novartis Capital Corp. 1,500 2.400% 2022 Novartis Capital Corp. 2,150 3.400% 2024 Novartis Capital Corp. 1,000 1.750% 2025 Novartis Capital Corp. 1,750 3.000% 2025 Novartis Capital Corp. 1,250 2.000% 2027 Novartis Capital Corp. 1,000 3.100% 2027 Novartis Capital Corp. 1,500 2.200% 2030 Novartis Capital Corp. 500 3.700% 2042 Novartis Capital Corp. 1,850 4.400% 2044 Novartis Capital Corp. 1,250 4.000% 2045 Novartis Capital Corp. 1,250 2.750% 2050 Credit ratings of Novartis AG Moody’s Investors Service S&P Global Ratings Short term P-1 A-1+ Long term A1 AA- Outlook Stable Stable Novartis Capital Corp. Principal amount USD 1,000,000,000 ISIN US66989HAM07 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 2.400% Coupon payment date May 17 and November 17, commencing May 17, 2017 Documentation SEC registered shelf registration First settlement date February 17, 2017 Issue price 99.449 Maturity date May 17, 2022 Joint book-runners Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS Bloomberg NOVNVX 2.4 05/17/2022 Novartis Capital Corp. Principal amount USD 1,500,000,000 ISIN US66989HAE80 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 2.400% Coupon payment date March 21 and September 21, commencing March 21, 2013 Documentation SEC registered shelf registration First settlement date September 21, 2012 Issue price 99.225 Maturity date September 21, 2022 Joint book-runners JP Morgan, Morgan Stanley, BNP Paribas, Citi, Bank of America Merrill Lynch, UBS Bloomberg NOVNVX 2.4 09/21/22 Novartis Capital Corp. Principal amount USD 2,150,000,000 ISIN US66989HAG39 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 3.400% Coupon payment date May 6 and November 6, commencing May 6, 2014 Documentation SEC registered shelf registration First settlement date February 21, 2014 Issue price 99.287 Maturity date May 6, 2024 Joint book-runners Goldman Sachs, Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, JP Morgan Bloomberg NOVNVX 3.4 05/06/24 Novartis Capital Corp. Principal amount USD 1,000,000,000 ISIN US66989HAP38 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 1.750% Coupon payment date February 14 and August 14, commencing August 14, 2020 Documentation SEC registered shelf registration First settlement date February 14, 2020 Issue price 99.852 Maturity date February 14, 2025 Joint book-runners Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho Bloomberg NOVNVX 1.75 02/14/2025 Novartis Capital Corp. Principal amount USD 1,750,000,000 ISIN US66989HAJ77 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 3.000% Coupon payment date May 20 and November 20, commencing May 20, 2016 Documentation SEC registered shelf registration First settlement date November 20, 2015 Issue price 99.010 Maturity date November 20, 2025 Joint book-runners Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS Bloomberg NOVNVX 3 11/20/2025 Novartis Capital Corp. Principal amount USD 1,250,000,000 ISIN US66989HAQ11 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 2.000% Coupon payment date February 14 and August 14, commencing August 14, 2020 Documentation SEC registered shelf registration First settlement date February 14, 2020 Issue price 99.909 Maturity date February 14, 2027 Joint book-runners Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho Bloomberg NOVNVX 2.0 02/14/2027 Novartis Capital Corp. Principal amount USD 1,000,000,000 ISIN US66989HAN89 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 3.100% Coupon payment date May 17 and November 17, commencing May 17, 2017 Documentation SEC registered shelf registration First settlement date February 17, 2017 Issue price 99.109 Maturity date May 17, 2027 Joint book-runners Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS Bloomberg NOVNVX 3.1 05/17/2027 Novartis Capital Corp. Principal amount USD 1,500,000,000 ISIN US66989HAR93 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 2.200% Coupon payment date February 14 and August 14, commencing August 14, 2020 Documentation SEC registered shelf registration First settlement date February 14, 2020 Issue price 99.869 Maturity date August 14, 2030 Joint book-runners Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho Bloomberg NOVNVX 2.2 08/14/2030 Novartis Capital Corp. Principal amount USD 500,000,000 ISIN US66989HAF55 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 3.700% Coupon payment date March 21 and September 21, commencing March 21, 2013 Documentation SEC registered shelf registration First settlement date September 21, 2012 Issue price 98.325 Maturity date September 21, 2042 Joint book-runners JP Morgan, Morgan Stanley, BNP Paribas, Citi, Bank of America Merrill Lynch, UBS Bloomberg NOVNVX 3.7 09/21/42 Novartis Capital Corp. Principal amount USD 1,850,000,000 ISIN US66989HAH12 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 4.400% Coupon payment date May 6 and November 6, commencing May 6, 2014 Documentation SEC registered shelf registration First settlement date February 21, 2014 Issue price 99.196 Maturity date May 6, 2044 Joint book-runners Goldman Sachs, Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, JP Morgan Bloomberg NOVNVX 4.4 05/06/44 Novartis Capital Corp. Principal amount USD 1,250,000,000 ISIN US66989HAK41 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 4.000% Coupon payment date May 20 and November 20, commencing May 20, 2016 Documentation SEC registered shelf registration First settlement date November 20, 2015 Issue price 98.029 Maturity date November 20, 2045 Joint book-runners Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS Bloomberg NOVNVX 4 11/20/2045 Novartis Capital Corp. Principal amount USD 1,250,000,000 ISIN US66989HAS76 Issuer Novartis Capital Corp., United States Guarantor Novartis AG, Switzerland Type Senior unsecured Coupon 2.750% Coupon payment date February 14 and August 14, commencing August 14, 2020 Documentation SEC registered shelf registration First settlement date February 14, 2020 Issue price 97.712 Maturity date August 14, 2050 Joint book-runners Citi, HSBC, Morgan Stanley, Mitsubishi UFJ Financial Group, Barclays, Deutsche Bank, Mizuho Bloomberg NOVNVX 2.75 08/14/2050 Disclaimer: The information provided on this website does not constitute investment advice, or an offer of, or an invitation or solicitation by, or on behalf of, Novartis AG or any of its subsidiaries, to subscribe for, purchase or sell any securities, including any of the securities described above and below. The information provided also does not constitute an offer, and may not be used for the purpose of an offer to, or a solicitation by, anyone in any jurisdiction or in any circumstances in which such an offer or solicitation is not authorized or is unlawful. You should always seek advice to determine whether governing law permits the use or possession of the information provided. Neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any direct or consequential loss arising from any use of the information provided. In particular, neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any third party content that may be viewed on this site. All information provided is also qualified in its entirety by reference to the relevant prospectuses, supplemental information and other documentation related to the securities described above and below. Related Links Fixing what’s lost in translation Exploring the future of access to healthcare in lower-income countries Tailoring tactics to tackle chronic disease in low-income countries Novartis Social Business Careers: improving health in lower income countries Novartis Navigate Patients and Caregivers Healthcare Professionals Researchers Job Seekers Journalists Investors Partners Suppliers Topics Clinical Trials COVID-19 Info Center ESG Explore Stories Diseases Locations Companies Sandoz Advanced Accelerator Applications Footer Bottom © 2021 Novartis AG Terms of Use Privacy Contacts Cookie Settings Site Map Novartis Site Directory This site is intended for a global audience Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies, select “Cookie settings” for managing the different cookies or select “Reject all” for using only strictly necessary cookies. You can change your cookie settings at any point of time by pressing the cookie settings link on the website. Cookie Settings Reject all Accept all